Symetryx Corp's Form 4 filing
NeuBase Therapeutics, Inc. (NBSE) · filed Sep 18, 2023
- Accession no.
- 0001991925-23-000005
- Filed
- Sep 18, 2023
- Trade date
- Sep 14-18, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $375.6K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Symetryx CorpCIK 0001991925 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 14, 2023 | Common Stock, Par Value $0.0001 per Share | SSaleDisposed | −129,108 | $1.44 | −$185,915.52 | 153,337 | Direct | |
| Sep 15, 2023 | Common Stock, Par Value $0.0001 per Share | SSaleDisposed | −103,337 | $1.26 | −$130,204.62 | 50,000 | Direct | |
| Sep 18, 2023 | Common Stock, Par Value $0.0001 per Share | SSaleDisposed | −50,000 | $1.19 | −$59,500 | 0 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.